Therapy timing, patient factors, and emerging combination interventions are guiding treatment decisions in multiple myeloma and lymphoma.

A 70-year-old white male, who had been diagnosed with IgA lambda multiple myeloma 4 months previously, was referred to the Mayo Clinic for further evaluation of anemia. The patient had required ...

Nat Clin Pract Gastroenterol Hepatol. 2007;4(2):111-115.

Multiple myeloma (MM) is a malignancy of terminally differentiated B cells. The diagnosis requires the presence of ≥ 10 % clonal plasma cells (PC) in the bone marrow or an extramedullary plasmacytoma ...

A study by the American Cancer Society has found that being overweight or obese increases a person’s risk of developing myeloma. Many people with other plasma cell diseases like MGUS or solitary ...

Multiple myeloma (MM) is a cancer that is found in plasma cells. When these malignant plasma cells are formed, they grow uncontrollably and produce what is known as a specific tumor called a ...

Further research is necessary to optimize treatment protocols and long-term surveillance strategies due to the potential risk of recurrence or progression to multiple myeloma. Solitary plasmacytoma ...

Multiple myeloma is a type of blood cancer that forms in plasma cells, white blood cells that produce infection-fighting antibodies. Multiple myeloma is not hereditary, meaning it is not passed ...

Multiple myeloma is a rare blood cancer that develops in the plasma cells, which are white blood cells that help you fight infection by making antibodies. Multiple myeloma starts in the plasma ...